Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry.


Journal

Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148

Informations de publication

Date de publication:
08 2022
Historique:
pubmed: 13 8 2022
medline: 19 8 2022
entrez: 12 8 2022
Statut: ppublish

Résumé

The Food and Drug Administration approved left atrial appendage occlusion with the Watchman device for patients who are at increased stroke risk and are suitable for oral anticoagulation but who have an appropriate reason to seek a nondrug alternative. These broad criteria raise the question of their interpretation in clinical practice. There is a lack of studies comprehensively evaluating the indications for Watchman implantation among a large series of patients from contemporary, real-world practice in the United States. We used the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry to identify Watchman procedures performed between 2016 and 2018. We assessed procedural indications for Watchman implantation in the United States and evaluated the association between procedural indications and in-hospital adverse events. A total of 38 314 procedures were included. The mean patient age was 76.1±8.1 years, and 58.9% were men. The mean CHA Among patients in the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry, the most common procedural indications for Watchman implantation were increased thromboembolic risk, history of major bleed, and high fall risk. A majority of patients had multiple procedural indications. High fall risk conferred a modestly increased risk of in-hospital adverse events.

Sections du résumé

BACKGROUND
The Food and Drug Administration approved left atrial appendage occlusion with the Watchman device for patients who are at increased stroke risk and are suitable for oral anticoagulation but who have an appropriate reason to seek a nondrug alternative. These broad criteria raise the question of their interpretation in clinical practice. There is a lack of studies comprehensively evaluating the indications for Watchman implantation among a large series of patients from contemporary, real-world practice in the United States.
METHODS
We used the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry to identify Watchman procedures performed between 2016 and 2018. We assessed procedural indications for Watchman implantation in the United States and evaluated the association between procedural indications and in-hospital adverse events.
RESULTS
A total of 38 314 procedures were included. The mean patient age was 76.1±8.1 years, and 58.9% were men. The mean CHA
CONCLUSIONS
Among patients in the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry, the most common procedural indications for Watchman implantation were increased thromboembolic risk, history of major bleed, and high fall risk. A majority of patients had multiple procedural indications. High fall risk conferred a modestly increased risk of in-hospital adverse events.

Identifiants

pubmed: 35959677
doi: 10.1161/CIRCOUTCOMES.121.008418
pmc: PMC9388561
mid: NIHMS1800955
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e008418

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL142765
Pays : United States
Organisme : NHLBI NIH HHS
ID : R56 HL142765
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Heart Rhythm. 2017 Sep;14(9):1302-1308
pubmed: 28577840
J Am Coll Cardiol. 2017 Jan 24;69(3):253-261
pubmed: 27816552
Eur Heart J. 2016 Aug;37(31):2465-74
pubmed: 26822918
Lancet. 2009 Aug 15;374(9689):534-42
pubmed: 19683639
Heart. 2011 May;97(9):762-5
pubmed: 21378010
J Am Coll Cardiol. 2013 Jul 9;62(2):108-118
pubmed: 23062528
J Am Coll Cardiol. 2020 Apr 7;75(13):1503-1518
pubmed: 32238316
Europace. 2015 Apr;17(4):642-6
pubmed: 25833883
JAMA. 2014 Nov 19;312(19):1988-98
pubmed: 25399274
J Am Coll Cardiol. 2012 Oct 16;60(16):1484-8
pubmed: 22999725
Heart Rhythm. 2011 Feb;8(2):188-93
pubmed: 21050893
Circ Arrhythm Electrophysiol. 2019 Apr;12(4):e006841
pubmed: 30939908
J Am Coll Cardiol. 2019 Jul 9;74(1):104-132
pubmed: 30703431
J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975
pubmed: 29103847
Am J Cardiol. 2015 Feb 1;115(3):378-84
pubmed: 25579887
Int J Cardiol Heart Vasc. 2019 Apr 09;23:100358
pubmed: 31008181
J Am Coll Cardiol. 2015 Jun 23;65(24):2614-2623
pubmed: 26088300
JACC Cardiovasc Interv. 2009 Jul;2(7):594-600
pubmed: 19628179
J Am Coll Cardiol. 2019 Dec 10;74(23):2878-2889
pubmed: 31806131
J Am Coll Cardiol. 2017 Mar 21;69(11):1427-1450
pubmed: 28025065
J Am Coll Cardiol. 2014 Jul 8;64(1):1-12
pubmed: 24998121
Am Heart J. 2006 Oct;152(4):720-3
pubmed: 16996847

Auteurs

Usama A Daimee (UA)

Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD (U.A.D.).

Yongfei Wang (Y)

Center for Outcomes Research and Evaluation Yale New Haven Health Services Corporation, New Haven, CT (Y.W., D.J.F., C.D., J.P.C., J.V.F.).

Frederick A Masoudi (FA)

Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (F.A.M., P.D.V.).

Paul D Varosy (PD)

Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (F.A.M., P.D.V.).

Daniel J Friedman (DJ)

Center for Outcomes Research and Evaluation Yale New Haven Health Services Corporation, New Haven, CT (Y.W., D.J.F., C.D., J.P.C., J.V.F.).
Section of Cardiovascular Medicine (D.J.F., J.P.C., J.V.F.), Yale University School of Medicine, New Haven, CT.

Chengan Du (C)

Center for Outcomes Research and Evaluation Yale New Haven Health Services Corporation, New Haven, CT (Y.W., D.J.F., C.D., J.P.C., J.V.F.).

Cristina Koutras (C)

American College of Cardiology Foundation, Washington, DC (C.K.).

Vivek Y Reddy (VY)

Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY (V.Y.R.).

Jacqueline Saw (J)

Division of Cardiology, Vancouver General Hospital, The University of British Columbia (J.S.).

Matthew J Price (MJ)

Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA (M.J.P.).

Fred M Kusumoto (FM)

Department of Cardiovascular Disease, Mayo Clinic, Jacksonville, FL (F.M.K.).

Jeptha P Curtis (JP)

Center for Outcomes Research and Evaluation Yale New Haven Health Services Corporation, New Haven, CT (Y.W., D.J.F., C.D., J.P.C., J.V.F.).
Section of Cardiovascular Medicine (D.J.F., J.P.C., J.V.F.), Yale University School of Medicine, New Haven, CT.

James V Freeman (JV)

Center for Outcomes Research and Evaluation Yale New Haven Health Services Corporation, New Haven, CT (Y.W., D.J.F., C.D., J.P.C., J.V.F.).
Section of Cardiovascular Medicine (D.J.F., J.P.C., J.V.F.), Yale University School of Medicine, New Haven, CT.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH